Patel Chem IPO: Date, Price Band & Launch Details
Patel chem Specialities Gears Up for Growth with IPO Funding for New Manufacturing Facility
Table of Contents
Patel Chem Specialities Limited is set to bolster its manufacturing capabilities and market presence with the proceeds from its upcoming Initial Public Offering (IPO). The company, a prominent manufacturer of cellulose- and starch-based pharmaceutical excipients, plans to utilize the funds for a significant capital expenditure, general corporate purposes, and issue-related expenses.
The registrar to the issue is MUFG Intime India Private Limited (formerly Link Intime India Private Limited).
IPO Proceeds: Fueling Strategic Expansion
The utilization of net proceeds from the IPO is strategically allocated to several key areas. A ample portion will be directed towards funding the capital expenditure requirement for establishing a new plant at Indrad,Mahesana. This facility will be dedicated to the manufacturing of critical pharmaceutical excipients, including Croscarmellose Sodium, Sodium Starch Glycolate (both Corn Starch Base & Potato Starch Base), and calcium Carboxymethylcellulose (CMC). The remaining funds will be used for general corporate purposes and to cover issue-related expenses.
Bhupesh Patel,Managing Director of Patel Chem Specialities,expressed optimism about the IPO’s impact. “The IPO proceeds will fuel our strategic expansion and strengthen our presence in both domestic and international markets,” Patel stated. “With a growing portfolio of pharmaceutical excipients and exports to over 15 countries, we are committed to timely and customized delivery through our advanced facilities in Vatva and Talod. The upcoming facility at Indrad, Mehsana will help us meet rising demand for key products like CCS, SSG, and Calcium CMC, and support our focus on innovation and customer-driven solutions.”
Swapnilsagar Vithalani,Co-founder and Director of Cumulative Capital Private,highlighted the company’s strong market position. “We are proud to partner with Patel Chem Specialities Limited for their IPO journey,” Vithalani commented. “The company’s strong foundation in pharmaceutical excipients, backed by a seasoned leadership team and robust export footprint, positions it well for sustainable growth in a global market that’s increasingly leaning on reliable, high-quality ingredients.This offering marks an vital milestone not just for the company,but for investors seeking value in a rapidly evolving pharmaceutical ecosystem. With the upcoming facility in Indrad, their scale and innovation potential are set to expand meaningfully.”
also Read | NFO Insight: Capitalmind Mutual Fund’s flexi cap fund opens for subscription. Will it help to manage current market volatility?
About Patel Chem Specialities: A Leader in Pharmaceutical Excipients
Established in 2008, Patel Chem Specialities Limited has carved a niche as a leading manufacturer of cellulose- and starch-based pharmaceutical excipients. The company is recognized for its unwavering commitment to global quality standards, ensuring its products are integral to drug formulation processes and meet stringent international benchmarks.
Innovation and Quality at the Forefront
With a dedicated in-house Research and Development (R&D) facility and an experienced technical team, Patel Chem Specialities is adept at offering customized, cost-effective, and innovative specialty chemical solutions across a diverse range of applications. This focus on innovation and customer-centric solutions underpins the company’s growth trajectory.
Robust Financial Performance and Capacity
As of FY25, Patel Chem specialities boasts an installed production capacity of 7,200 metric tons per year, operating at a high capacity utilization rate of 89%.The company demonstrated strong financial performance in FY25, reporting an Operating Revenue of Rs 105.09 crore, with an EBITDA of Rs 15.27 crore and a Net Profit of Rs 10.57 crore. This robust financial health, coupled with strategic expansion plans, positions Patel Chem Specialities for continued success in the pharmaceutical ingredients market.